Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of WPV01 in Patients With Mild to Moderate COVID-19

NCT06197217 is registered in ClinicalTrials.gov with Westlake Pharmaceuticals (Hangzhou) Co., Ltd. as lead sponsor.

NCT NCT06197217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06197217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of WPV01 in Patients With Mild to Moderate COVID-19
Lead sponsor
Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
June 14, 2023
Completion date
September 20, 2023
Enrollment
1,350 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mild to moderate covid-19